Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationBG ControlPreventionIssue 568Special Edition - Best of 2011

Nicotine Can Raise A1c by 34 Percent

Strong link between nicotine and diabetes complications....
Advertisement

Scientists have reported the first strong evidence implicating nicotine as the main culprit responsible for persistently elevated blood sugar levels -- and the resulting increased risk of serious health complications -- in people who have diabetes and smoke. 

The discovery also may have implications for people with diabetes who are using nicotine-replacement therapy for extended periods in an attempt to stop smoking.

Xiao-Chuan Liu, Ph.D., who presented the results stated that, "This is an important study and it is the first study to establish a strong link between nicotine and diabetes complications. If you're a smoker and have diabetes, you should be concerned and make every effort to quit smoking."

Doctors have known for years that smoking increases the risk of developing complications. Studies also show that smokers with diabetes have higher levels of HbA1c than nonsmokers with diabetes. However, nobody knew the exact substance in cigarette smoke responsible for the elevation in HbA1c. Liu and colleagues suspected it may be nicotine and set out to check nicotine's effects on HbA1c. Using human blood samples, they showed that concentrations of nicotine similar to those found in the blood of smokers did, indeed, raise levels of HbA1c.

"Nicotine caused levels of HbA1c to rise by as much as 34 percent," said Liu, who is with California State Polytechnic University in Pomona, Calif. "No one knew this before. The higher the nicotine levels, the more HbA1c is produced."

Doctors could use data from this study as a new basis for encouraging patients with diabetes to quit smoking, Liu said. What about nicotine patches, electronic cigarettes, and other stop-smoking products? Liu pointed out that people tend to use those products for only brief periods, and that the benefits of permanently stopping smoking may outweigh any risk from temporary elevations in HbA1c. However, the study may raise concern over the long term use of such products, he added.

Presented at the 241st National Meeting & Exposition of the American Chemical Society

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2011 and appeared in  MedicationBG ControlPreventionIssue 568Special Edition - Best of 2011

Past five issues: Diabetes Clinical Mastery Series Issue 247 | Issue 787 | Diabetes Clinical Mastery Series Issue 246 | SGLT-2 Inhibitors Special Edition June 2015 | Issue 786 |

2015 Most Popular Articles:

Triple Therapy Improves Glycemia in Type 1 Diabetes
Posted June 19, 2015
A Dual SGLT1/SGLT2 Inhibitor Can be a Treatment Option in Type 1 Diabetics
Posted June 12, 2015
High Fiber Diets Reduce Risk of Diabetes
Posted June 04, 2015
Canagliflozin and Its Effects on Weight Loss and BP
Posted June 12, 2015
Efficacy and Safety of an SGLT-2 Inhibitor with Insulin for Type 2s
Posted May 28, 2015
Skin Bacteria a Cause of Diabetes?
Posted June 12, 2015
Blood Biomarkers May Predict Risk of Severe Hypoglycemia
Posted June 12, 2015
Are Postprandial Levels in T1 Patients Impacted by More Than Carbohydrates?
Posted May 28, 2015
Lilly Insulin: A Better Alternative than Lantus?
Posted June 19, 2015
Tight Blood Glucose Control and Cardiovascular Disease
Posted June 12, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Have you recommended the use of an SGLT-2 inhibitor to any of your type 1 patients?

CME/CE of the Week
Gestational Diabetes Education in an Obstetric Office
Lois Exelbert, RN, CDE, BC-ADM, LCCE

Category: Nursing
CE Credits: 1.0